CXCR4 in breast cancer: oncogenic role and therapeutic targeting
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Chemokines are 8-12 kDa peptides that function as chemoattractant cytokines and are involved in cell activation, differentiation, and trafficking. Chemokines bind to specific G-protein-coupled seven-span transmembrane receptors. Chemokines play a fundamental role in the regulation of a variety of cellular, physiological, and developmental processes. Their aberrant expression can lead to a variety of human diseases including cancer. C-X-C chemokine receptor type 4 (CXCR4), also known as fusin or CD184, is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12). CXCR4 belongs to the superfamily of the seven transmembrane domain heterotrimeric G protein-coupled receptors and is functionally expressed on the cell surface of various types of cancer cells. CXCR4 also plays a role in the cell proliferation and migration of these cells. Recently, CXCR4 has been reported to play an important role in cell survival, proliferation, migration, as well as metastasis of several cancers including breast cancer. This review is mainly focused on the current knowledge of the oncogenic role and potential drugs that target CXCR4 in breast cancer. Additionally, CXCR4 proangiogenic molecular mechanisms will be reviewed. Strict biunivocal binding affinity and activation of CXCR4/CXCL12 complex make CXCR4 a unique molecular target for prevention and treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299 · cited 1×
“Bone Increased CXCR4 expression is present in breast cancer cells metastasized to bone.(84) Some bone cells such as osteoblasts produce SDF-1 (CXCL12), and this is the reason that breast cancer cells can easily metastasize to bone.”
BackgroundChemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870 · cited 1×
“38 Nuclear factor kappa-light-chain enhancer of activated B cells (NF-κ B): Similar to HIF, there is an NF-κ B binding site within in the CXCR4 gene promoter.”
BackgroundHelbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
Regulation of CXCL12 expression by canonical Wnt signaling in bone marrow stromal cells
Tamura, M., Sato, M. M., & Nashimoto, M. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.01.021 · Cited by 51
Cited by
Li, W., Ma, H., Zhang, J., Zhu, L., Wang, C., & Yang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-14364-2 · Cited by 454
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Bernard, V., Semaan, A., Huang, J., San Lucas, F. A., Mulu, F. C., Stephens, B. M., Guerrero, P. A., Huang, Y., Zhao, J., Kamyabi, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1955 · Cited by 389
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Zhou, W., Guo, S., Liu, M., Burow, M. E., & Wang, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830111531 · Cited by 278
The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond
Ullah, T. R. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100253 · Cited by 141
Qureshi, R., Picon-Ruiz, M., Sho, M., Van Booven, D., Nunes de Paiva, V., Diaz-Ruano, A. B., Ince, T. A., & Slingerland, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111672 · Cited by 37
Bhattarai, S., Mackeyev, Y., Venkatesulu, B. P., Krishnan, S., & Singh, P. K. (2021) · Nanoscale · doi:10.1039/d1nr05385j · Cited by 22
Metadata
- Authors
- Yao, Q., Xu, C., Zhao, H., & Chen, H.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-08
- Volume
- 9
- Pages
- 4953
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2110836783
- Cited by
- 208
- References
- 5
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.